ATE414711T1 - Polymerstabilisierte proteinasen - Google Patents

Polymerstabilisierte proteinasen

Info

Publication number
ATE414711T1
ATE414711T1 AT02744682T AT02744682T ATE414711T1 AT E414711 T1 ATE414711 T1 AT E414711T1 AT 02744682 T AT02744682 T AT 02744682T AT 02744682 T AT02744682 T AT 02744682T AT E414711 T1 ATE414711 T1 AT E414711T1
Authority
AT
Austria
Prior art keywords
proteinases
polymer
stabilized
admixture
stabilization
Prior art date
Application number
AT02744682T
Other languages
English (en)
Inventor
Merry Sherman
Alexa Martinez
Shyam Bhaskaran
L Williams
Mark Saifer
John A French
Original Assignee
Mountain View Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mountain View Pharmaceuticals filed Critical Mountain View Pharmaceuticals
Application granted granted Critical
Publication of ATE414711T1 publication Critical patent/ATE414711T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02744682T 2001-06-28 2002-06-28 Polymerstabilisierte proteinasen ATE414711T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89407101A 2001-06-28 2001-06-28
US10312802A 2002-03-22 2002-03-22

Publications (1)

Publication Number Publication Date
ATE414711T1 true ATE414711T1 (de) 2008-12-15

Family

ID=26800115

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02744682T ATE414711T1 (de) 2001-06-28 2002-06-28 Polymerstabilisierte proteinasen

Country Status (8)

Country Link
US (1) US7229810B2 (de)
EP (1) EP1421175B1 (de)
AT (1) ATE414711T1 (de)
AU (1) AU2002345938A1 (de)
CA (1) CA2450985A1 (de)
DE (1) DE60229958D1 (de)
DK (1) DK1421175T3 (de)
WO (1) WO2003002716A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020065397A1 (en) * 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
WO2003064605A2 (en) 2002-01-28 2003-08-07 Ambion, Inc. Crude biological derivatives competent for nucleic acid detection
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
JP2007530440A (ja) * 2003-05-12 2007-11-01 アフィーマックス・インコーポレイテッド 新規ポリ（エチレングリコール）修飾化合物およびその用途
PL1625156T3 (pl) * 2003-05-12 2013-03-29 Affymax Inc Peptydy wiążące się do receptora erytropoetyny
CN1849141A (zh) * 2003-05-12 2006-10-18 阿费麦克斯公司 用于聚(乙二醇)修饰的肽的间隔臂部分
EP1814910A4 (de) * 2004-11-11 2009-04-29 Affymax Inc Neue am erythropoietinrezeptor bindende peptide
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
EP1859038B1 (de) * 2005-02-11 2010-08-04 Invitrogen Dynal AS Verfahren zur isolierung von nukleinsäuren mit verwendung von ethylenglykol-multimeren
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US20070212865A1 (en) * 2006-03-08 2007-09-13 Craig Amrine Method for planarizing vias formed in a substrate
US7964350B1 (en) 2007-05-18 2011-06-21 Applied Biosystems, Llc Sample preparation for in situ nucleic acid analysis
EP2955233A1 (de) * 2008-12-19 2015-12-16 Life Technologies Corporation Proteinase K Inhibitore, Verfahren und Zusammensetzungen davon
JP2021517143A (ja) * 2018-03-14 2021-07-15 バ、ヨン Ｐｅｇ化不凍タンパク質およびそれを作製する方法およびそれを使用する方法
CN118165964B (zh) * 2024-04-11 2025-01-24 铭诚惠众(江苏)药物研究有限公司 一种重组蛋白酶k的纯化方法及其应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
JPS5599189A (en) 1979-01-22 1980-07-28 Mihama Hisaharu Modified uricase free from antigenicity and its preparation
JPS5816685A (ja) 1981-07-22 1983-01-31 Takeda Chem Ind Ltd 固定化酵素，その製造法および製剤
JPS57118789A (en) 1981-01-13 1982-07-23 Eisai Co Ltd Modified streptokinase and its preparation
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4844897A (en) 1985-09-13 1989-07-04 Hiroshi Maeda Anti-tumor protease preparations
JPS6255079A (ja) 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
US5278062A (en) * 1987-04-03 1994-01-11 Amgen Proteolytic enzymes
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5006333A (en) * 1987-08-03 1991-04-09 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
CA1340807C (en) * 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5246849A (en) * 1988-04-12 1993-09-21 Enzon, Inc. Thermally stable serine proteases
JP2958019B2 (ja) * 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
US5498523A (en) * 1988-07-12 1996-03-12 President And Fellows Of Harvard College DNA sequencing with pyrophosphatase
US4962020A (en) * 1988-07-12 1990-10-09 President And Fellows Of Harvard College DNA sequencing
JPH02219571A (ja) 1989-02-20 1990-09-03 Kanebo Ltd 修飾プロテアーゼ及びその製造法
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5455166A (en) * 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
ZA927323B (en) 1991-09-24 1993-08-30 Keygene Nv Selective restriction fragment amplification: A general method for DNA fingerprinting
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5321095A (en) * 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5482996A (en) * 1993-12-08 1996-01-09 University Of Pittsburgh Protein-containing polymers and a method of synthesis of protein-containing polymers in organic solvents
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JPH10510516A (ja) * 1994-12-07 1998-10-13 ノボ ノルディスク アクティーゼルスカブ アレルゲン性を減らしたポリペプチド
US5837517A (en) * 1995-05-05 1998-11-17 Novo Nordisk A/S Protease variants and compositions
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
KR100591553B1 (ko) * 1996-11-04 2006-06-19 노보자임스 에이/에스 섭틸라제 변종과 조성물
US6416756B1 (en) * 1997-01-10 2002-07-09 Novozymes A/S Modified protease having 5 to 13 covalently coupled polymeric molecules for skin care
AU740207B2 (en) * 1997-02-06 2001-11-01 Novozymes A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
DE69838551T2 (de) 1997-06-25 2008-07-24 Novozymes A/S Modifiziertes polypeptid
US5847110A (en) * 1997-08-15 1998-12-08 Biomedical Frontiers, Inc. Method of reducing a schiff base
US6495136B1 (en) 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
CA2333491A1 (en) 1998-07-17 2000-01-27 Novozymes A/S A polypeptide-polymer conjugate with improved wash performance
PL202799B1 (pl) 1998-08-06 2009-07-31 Mountain View Pharmaceuticals Sposób izolowania urykazy w postaci tetramerycznej oraz wyizolowana tetrameryczna urykaza
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US6964764B2 (en) * 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin

Also Published As

Publication number Publication date
EP1421175A4 (de) 2004-12-08
US7229810B2 (en) 2007-06-12
DE60229958D1 (de) 2009-01-02
US20030012777A1 (en) 2003-01-16
EP1421175A2 (de) 2004-05-26
WO2003002716A2 (en) 2003-01-09
WO2003002716A3 (en) 2003-10-16
DK1421175T3 (da) 2009-03-23
AU2002345938A1 (en) 2003-03-03
EP1421175B1 (de) 2008-11-19
CA2450985A1 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
DE60229958D1 (de) Polymerstabilisierte proteinasen
ATE542922T1 (de) 2'-terminator-assoziierte pyrophosphorolyse- aktivierte polymerisierung
DE60329220D1 (de) Antisense-entwurf
DK1232502T3 (da) Magnetiske glaspartikler, fremgangsmåde til deres fremstilling samt anvendelser deraf
EP1608732A4 (de) Zusammensetzungen und verfahren zur verwendung einer synthetischen dnase i
ATE469911T1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
DE60123389D1 (de) Stabile, wässerige zusammensetzungen zur behandlung von oberflächen , insbesondere geweben
MXPA03002572A (es) Secuencias de nucleotidos que intervienen en la fertilidad de los machos y metodo de su uso.
WO2004096842A3 (en) Sars virus nucleotide and amino acid sequences and uses thereof
DE60138715D1 (de) Tnf-rezeptor-ähnliche moleküle und deren anwendungen
DE60216278D1 (de) Polyoxyalkylen-ammoniumsalze und ihre verwendung als antistatika
DZ3182A1 (fr) Solution acide sulfoisophtalique et procédé avec cette solution.
WO2007040592A8 (en) Making nucleic acid sequences in parallel and use
WO2002102825A3 (en) Fluorescently labelled locked nucleic acids
DE60239729D1 (de) Männliche fertilitätvermittelnde nukleotidsequenzen und deren verwendung
BRPI0414370A (pt) enzimas modificadas, processos para produzir enzimas modificadas e usos das mesmas
BR9904054A (pt) Proteìnas que se ligam a diarilsulfoniluréia
WO2000053776A3 (en) Human kallikrein-like genes
EP1352072A4 (de) Formulierungen für die zuführung von nukleinsäuren
WO2005047462A3 (en) Universal control for nucleic acid amplification
ATE369429T1 (de) Strukturproteine des virus, welches die pankreas- krankheit bei fischen verursacht, und ihre verwendungen
BR0213964A (pt) sistema de expressão de ácido nucléico regulada
WO2002079495A3 (en) Genomics applications for modified oligonucleotides
WO2001053352A3 (en) Sperm specific proteins
BRPI0513267A (pt) variantes melhoradas de aprotinina

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1421175

Country of ref document: EP